[1] | Lindoso JAL, Moreira CHV, Cunha MA , et al. Visceral leishmaniasis and HIV coinfection: current perspectives[J]. HIV AIDS, 2018,10:193-201. | [2] | Zhong YY, Wang JY . Clinical analysis of AIDS coinfected with visceral leishmaniasis[J]. Chin J Prac Med, 2004,4(16):41-42. (in Chinese) | [2] | ( 钟玉映, 王俊云 . 艾滋病合并感染黑热病的临床分析[J]. 中华实用医药杂志, 2004,4(16):41-42.) | [3] | Gu Y, Ma CH, Zhou LB . HIV positive patient coinfected with visceral leishmaniasis:a case report[J]. JPMT, 2008(16):2156-2157. (in Chinese) | [3] | ( 古月, 马纯华, 周利波 . HIV抗体阳性患者感染黑热病1例[J]. 实用医技杂志, 2008(16):2156-2157.) | [4] | Zhang GX, Cao BL , Xing JY. HIV coinfected with visceral leishmaniasis:a case report [J]. Chin J Derm Venereol, 2010, 24(11): 1072, 1074. (in Chinese) | [4] | ( 张更新, 曹碧兰, 幸建英 . 艾滋病合并感染黑热病1例[J]. 中国皮肤性病学杂志, 2010, 24(11): 1072, 1074.) | [5] | Xia HJ, Yi YL, Liao YQ . Analysis of misdiagnosis about three cases with leishmaniasis and HIV co-infection[J]. Chin J Derm Venereol, 2011,25(7):567-568. (in Chinese) | [5] | 夏洪娇, 易运林, 廖永强 . 黑热病合并HIV感染3例误诊分析[J]. 中国皮肤性病学杂志, 2011,25(7):567-568. | [6] | Baoyixiamu·ABBKL, Pan KJ Maimaitiaili·XBL , et al. AIDS with kala-azar:a case report[J]. Chin J Viral Dis, 2012,2(6):75-76. (in Chinese) | [6] | ( 包依夏姆·阿巴拜克力, 潘珂君 买买提艾力·吾布力, , 等. 艾滋病合并黑热病1例分析[J]. 中国病毒病杂志, 2012,2(6):75-76.) | [7] | Song SH, Gui XE . Follow-up of a patient with Leishmania and human immunodeficiency virus co-infection who received prolonged sodium stibogluconate treatments[J]. Chin J Parasitol Parasit Dis, 2018,36(2):148-152. (in Chinese) | [7] | ( 宋世会, 桂希恩 . 葡萄糖酸锑钠长疗程治疗1例利什曼原虫与人类免疫缺陷病毒合并感染患者的追踪观察[J]. 中国寄生虫学与寄生虫病杂志, 2018,36(2):148-152.) | [8] | Guan LR, Gao CH . Leishmaniasis and its control[J]. Chin J Parasitol Parasit Dis, 2018,36(4):418-424, 428. (in Chinese) | [8] | ( 管立人, 高春花 . 利什曼病及其防治[J]. 中国寄生虫学与寄生虫病杂志, 2018,36(4):418-424, 428.) | [9] | Lindoso JA ,Cota GF, da Cruz AM, et al. Visceral leishmaniasis and HIV coinfection in Latin America[J]. PLoS Negl Trop Dis, 2014,8(9):e3136. | [10] | Lima IP, Müller MC ,HolandaTA, et al. Human immunodeficiency virus/Leishmania infantum in the frst foci of urban American visceral leishmaniasis: clinical presentation from 1994 to 2010[J]. Rev Soc Bras Med Trop, 2013,46(2):156-160. | [11] | Wang J, Guan LR . Leishmaniasis and HIV coinfection:a problem of leishmaniasis[J]. Foreign Med Sci Parasit Dis, 2004,31(4):169-172. (in Chinese) | [11] | ( 王捷, 管立人 . 利什曼原虫与艾滋病病毒的合并感染: 利什曼病防治上值得重视的一个问题[J]. 国外医学(寄生虫病分册), 2004,31(4):169-172.) | [12] | Cota GF, de Sousa MR, de Mendon?a AL , et al. Leishmania-HIV coinfection: clinical presentation and outcomes in an urban area in Brazil[J]. LoS Negl Trop Dis, 2014,8(4):e2816. | [13] | WHO. Control of the leishmaniases[R]. Geneva: World Health Organization, 2010. | [14] | Srivastava P, Dayama A, Mehrotra S , et al. Diagnosis of visceral leishmaniasis[J]. Trans R Soc Trop Med Hyg, 2011,105(1):1-6. | [15] | Burza S, Croft SL, Boelaert M . Leishmaniasis--author’s reply[J]. Lancet, 2019,393(10174):872-873. | [16] | Nuzum E, White F, Thakur C , et al. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood[J]. J Infect Dis, 1995,171(3):751-754. | [17] | de Ruiter CM, van der Veer C, Leeflang MM , et al . Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy[J]. J Clin Microbiol, 2014,52(9):3147-3155. | [18] | Mary C, Faraut F, Lascombe L , et al. Quantifcation of Leishmania infantum DNA by a real-time PCR assay with high sensitivity[J]. J Clin Microbiol, 2004,42:5249-5255. | [19] | Bourgeois N, Bastien P, Reynes J , et al. ‘Active chronic visceral leishmaniasis’ in HIV-1-infected patients demonstrated by biological and clinical long-term followup of 10 patients[J]. HIV Med, 2010,11(10):670-673. | [20] | Cota GF, de Sousa MR, Demarqui FN , et al . The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis[J]. PLoS Negl Trop Dis, 2012,6(5):e1665. | [21] | Cunningham J, Hasker E, Das P , et al. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis[J]. Clin Infect Dis, 2012,55(10):1312-1319. | [22] | Cota GF, de Sousa MR, Nogueira BM , et al . Comparison of parasitological, serological, and molecular tests for visceral leishmaniasis in HIV-infected patients: a cross-sectional delayed-type study[J]. Am J Trop Med Hyg, 2013,89(3):570-577. | [23] | Riera C, Fisa R, Lopez P , et al. Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: value in diagnosis and post-treatment follow-up[J]. Eur J Clin Microbiol Infect Dis, 2004,23(12):899-904. | [23] | Frézard F, Demicheli C, Ribeiro RR . Pentavalent antimonials: new perspectives for old drugs[J]. Molecules, 2009,14(7):2317-2336. | [24] | Croft SL, Yardley V . Chemotherapy of leishmaniasis[J]. Curr Pharm Des, 2002,8(4):319-342. | [26] | Pintado V, López-Vélez R . HIV-associated visceral leishmaniasis[J]. Clin Microbiol Infect, 2001,7(6):291-300. | [27] | Cota GF, de Sousa MR, Fereguetti TO , et al . Effcacy of antiLeishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison[J]. PLoS Negl Trop Dis, 2013,7(5):e2195. | [28] | Ritmeijer K, Dejenie A, Assefa Y , et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection[J]. Clin Infect Dis, 2006,43(3):357-364. | [29] | World Heath Organization . Control of the leishmaniases[M]. Geneva: WHO, 2010. | [30] | Sinha PK, van Griensven J, Pandey K , et al . Liposomal amphotericin B for visceral leishmaniasis in human immunodefciency virus-coinfected patients: 2-year treatment outcomes in Bihar, India[J]. Clin Infect Dis, 2011,53(7):e91-e98. | [31] | Balasegaram M, Ritmeijer K, Lima MA , et al. Liposomal amphotericin B as a treatment for human leishmaniasis[J]. Expert Opin Emerg Drugs, 2012,17(4):493-510. | [32] | Sundar S, Singh A . Chemotherapeutics of visceral leishmaniasis: present and future developments[J]. Parasitology, 2018,145(4):481-489. | [33] | Dorlo TP, Huitema AD, Beijnen JH , et al. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis[J]. Antimicrob Agents Chemother, 2012,56(7):3864-3872. | [34] | Sindermann H, Engel KR, Fischer C , et al. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection[J]. Clin Infect Dis, 2004,39(10):1520-1523. | [35] | Garg R, Tremblay MJ . Miltefosine represses HIV-1 replication in human dendritic cell/T-cell cocultures partially by inducing secretion of type-I interferon[J]. Virology, 2012,432(2):271-276. | [36] | Hendrickx S, Boulet G, Mondelaers A , et al. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum[J]. Parasitol Res, 2014,113(5):1875-1881. | [37] | Singh N, Kumar M, Singh RK . Leishmaniasis: current status of available drugs and new potential drug targets[J]. Asian Pac J Trop Med, 2012,5(6):485-497. | [38] | Kuhlencord A, Maniera T, Eibl H , et al. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice[J]. Antimicrob Agents Chemother, 1992,36(8):1630-1634. | [39] | Mahajan R, Das P, Isaakidis P , et al. Combination treatment for visceral leishmaniasis patients coinfected with human immunodefciency virus in India[J]. Clin Infect Dis, 2015,61(8):1255-1262. | [40] | López-Vélez R, Videla S, Márquez M , et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients[J]. J Antimicrob Chemother, 2004,53(3):540-543. | [41] | Molina I, Falcó V, Crespo M , et al. Effcacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients[J]. J Antimicrob Chemother, 2007,60(4):837-842. | [42] | Diro E, Ritmeijer K, Boelaert M , et al. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study[J]. PLoS Negl Trop Dis, 2015,9(10):e0004087. | [43] | Marques N, Sá R, Coelho F , et al. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients[J]. Scand J Infect Dis, 2008,40(6/7):523-526. | [44] | Burza S, Mahajan R, Sinha PK , et al. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)[J]. PLoS Negl Trop Dis, 2014,8(8):e3053. | [45] | van Griensven J, Diro E, Lopez-Velez R , et al. HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals[J]. Lancet Infect Dis, 2013,13(3):251-259. |
|